ARA-290 · Research brief

Choose ARA-290 Vial Size — Dosing & Storage Guide

Real Peptides Research TeamEditorial

Updated July 9, 202611 min read

56 WORDS

Short answer

Key takeaways

ARA-290 reconstituted with bacteriostatic water has a maximum 28-day refrigerated stability window at 2–8°C. Vial size must match your protocol's total peptide requirement within that timeframe.
Calculate total peptide consumption before comparing unit pricing. A 50mg vial is not cost-effective if your study only requires 12mg and the remaining 38mg expires unused.
Every needle puncture through the vial stopper introduces contamination risk and accelerates oxidative degradation. Smaller vials accessed fewer times over shorter periods maintain higher peptide integrity.
Multi-vial procurement strategies (e.g., six 5mg vials instead of one 30mg vial) cost 15–20% more upfront but eliminate the risk of losing an entire batch to a single storage failure or protocol change.
Facilities without dedicated, temperature-logged peptide refrigerators should default to smaller vial sizes. Standard lab refrigerators with frequent door-opening create temperature fluctuations that compound degradation risk in long-term stored vials.

Most researchers choose ARA-290 vial size based on price per milligram. And end up wasting peptide. A 10mg vial costs less per unit than a 5mg vial, but if your protocol only requires 6mg total over 28 days, you're discarding 4mg of active compound that cannot be re-frozen or stored beyond the bacteriostatic water stability window. The real cost isn't the unit price; it's the amount you'll discard when the 28-day post-reconstitution window expires before you finish the vial.

Our team has guided hundreds of research facilities through peptide procurement decisions. The gap between choosing correctly and choosing expensively comes down to three variables most suppliers never discuss: your protocol's total peptide requirement, your storage constraints, and whether you're running concurrent studies that could share a larger vial.

How do you choose the right ARA-290 vial size for your research protocol?

Choose ARA-290 vial size by calculating your protocol's total peptide requirement over 28 days. The maximum stability window for reconstituted peptide stored at 2–8°C. If your study requires 300mcg per injection twice weekly for four weeks, that's 2,400mcg (2.4mg) total. A 5mg vial provides sufficient margin for measurement error and wastage; a 10mg vial means discarding 7.6mg of peptide. Match vial size to consumption, not to bulk pricing.

The most common procurement error isn't buying too little ARA-290. It's buying too much and losing half the vial to expiration. ARA-290 (also called Cibinetide or pHBSP) is a synthetic peptide derived from erythropoietin that activates the innate repair receptor without stimulating erythropoiesis. It's used extensively in neuroprotection, tissue repair, and metabolic dysfunction studies. Lyophilised peptide is stable for years at −20°C, but once you add bacteriostatic water, the countdown starts: 28 days maximum refrigerated stability before degradation renders it unreliable for research.

This guide covers the three core decision factors for choosing ARA-290 vial size, the storage failure modes that waste more peptide than measurement error ever will, and the protocol-specific scenarios that determine whether multi-vial or single-vial procurement makes sense.

Calculate Total Protocol Peptide Requirement First

Before you compare vial sizes, calculate your study's total peptide consumption across the post-reconstitution stability window. ARA-290 dosing in published neuroprotection studies typically ranges from 1–4mg per injection administered subcutaneously, with frequency varying from daily to twice weekly depending on the research model. A metabolic dysfunction protocol might use 2mg per dose three times weekly for four weeks. That's 24mg total peptide requirement. A neuroprotection study might require 500mcg daily for ten days. 5mg total.

The stability constraint is non-negotiable: once reconstituted with bacteriostatic water, ARA-290 must be used within 28 days when stored at 2–8°C. Temperature excursions above 8°C accelerate peptide bond hydrolysis and oxidation of the methionine residues critical to receptor binding affinity. Neither visual inspection nor pH testing can detect this degradation. Potency loss is invisible until your experimental results show unexplained variability.

Work backward from your timeline. If your protocol spans six weeks but requires only 8mg total peptide, splitting procurement into two 5mg vials. Reconstituting the second vial only when the first is depleted. Eliminates waste entirely. If your protocol requires 18mg over four weeks, a single 20mg vial used continuously stays within the stability window. The error most labs make is buying a 50mg vial for a 12mg protocol because the per-milligram cost is 40% lower. Then discarding 38mg when the 28-day window closes.

Account for measurement variance and transfer loss. Reconstituting a 5mg vial with 2mL bacteriostatic water yields a 2.5mg/mL solution, but extracting the final 0.1mL from the vial is difficult without drawing air or leaving residual peptide on the stopper. Build a 10–15% overage into your calculation: if you need exactly 5mg, specify a 6mg vial to cover pipetting error and dead volume.

Match Vial Size to Storage Capacity and Access Patterns

Vial size isn't just about peptide quantity. It's about how many times you'll access the vial and whether your refrigeration setup can maintain stable 2–8°C conditions throughout the study. Every time you puncture the stopper with a needle, you introduce contamination risk and allow small amounts of air into the solution, which accelerates oxidative degradation. A 50mg vial accessed daily for 28 days experiences 28 puncture events; a 5mg vial used over seven days experiences seven.

Larger vials make sense when multiple researchers are drawing from the same stock concurrently, but only if your facility has a dedicated peptide refrigerator with temperature logging and restricted access. Standard laboratory refrigerators that are opened 40 times per day for general reagent access create temperature fluctuations of 3–5°C every time the door opens. These fluctuations compound over 28 days. If your ARA-290 storage shares space with enzyme stocks, media bottles, and lunch containers, smaller vials reduce the cumulative temperature exposure per peptide molecule.

Consider splitting large-volume requirements across multiple smaller vials rather than consolidating into one large vial. A 30mg protocol requirement could be filled with six 5mg vials reconstituted one at a time, or one 30mg vial accessed continuously. The six-vial approach costs 15–20% more upfront but eliminates the risk of losing the entire 30mg stock to a single refrigeration failure, contamination event, or accidental room-temperature exposure. Our team has found that facilities running protocols above 20mg total requirement consistently report better data consistency when using a multi-vial strategy. The incremental cost is insurance against catastrophic loss.

Reconstitution volume matters here. A 10mg vial reconstituted with 5mL bacteriostatic water yields a 2mg/mL solution. Easy to measure accurately with standard pipettes. A 50mg vial reconstituted with 5mL yields 10mg/mL, which requires dilution for protocols using sub-milligram doses. Every dilution step introduces measurement error and contamination risk. If your dosing requires concentrations below 1mg/mL, smaller vials with lower reconstitution volumes are inherently more precise.

Understand the Hidden Costs of Bulk Vial Purchasing

The price-per-milligram advantage of large vials disappears when you calculate cost-per-usable-milligram. A 50mg vial at $8 per milligram costs $400 total. A 10mg vial at $12 per milligram costs $120 total. If your protocol uses only 12mg over 28 days, the 50mg vial delivers $144 of usable peptide and $256 of waste. An effective cost of $12 per usable milligram, identical to the smaller vial but with substantially higher capital outlay and disposal requirements.

Disposal isn't trivial. ARA-290 is a biologically active peptide that requires chemical waste handling under most institutional biosafety protocols. Discarding 38mg of reconstituted peptide means logging, neutralizing, and disposing of 15–19mL of biological waste solution. Smaller vials generate proportionally less waste and lower administrative burden. For research teams operating under constrained budgets or institutional waste disposal caps, this isn't a minor consideration.

The bulk-buying reflex works for stable reagents with years of shelf life. It fails for peptides with fixed post-reconstitution windows. Lyophilised ARA-290 stored at −20°C is stable for 24–36 months, but most labs don't have the −20°C capacity to store six months of backup vials. If your freezer space is limited, buying closer to your immediate need and reordering as protocols progress is more cost-effective than pre-purchasing a year's supply and losing half to degradation because you couldn't store it correctly.

Account for protocol variability. Research timelines shift. Animal models experience unexpected attrition. Preliminary results trigger early study termination or extension. A 50mg vial purchased for a 12-week study that gets terminated at week six leaves you with 35mg of peptide and no immediate use for it. Smaller vials provide flexibility to pause procurement when studies shift without stranding capital in unusable inventory. The most experienced research teams we work with deliberately under-order initial vial sizes and scale up only after confirming protocol stability. The modest per-milligram premium is offset by elimination of waste from protocol changes.

ARA-290 Vial Size: Dosing & Storage Comparison

| Vial Size | Typical Reconstitution Volume | Resulting Concentration | Ideal Protocol Duration | Access Frequency Risk | Cost Efficiency | Professional Assessment | |---|---|---|---|---|---| | 2mg | 1mL | 2mg/mL | 7–10 days, low-frequency dosing | Minimal. Fewer punctures | Premium per-mg cost, zero waste for short studies | Best for pilot studies or single-animal preliminary trials where timeline certainty is low | | 5mg | 2mL | 2.5mg/mL | 14–21 days, moderate-frequency dosing | Low. Optimal puncture-to-volume ratio | Balanced cost, minimal overage | Standard choice for most neuroprotection and metabolic research protocols with defined timelines | | 10mg | 4mL | 2.5mg/mL | 28 days, daily or high-frequency dosing | Moderate. 20–28 punctures typical | Good cost-per-mg if fully consumed | Suitable for continuous multi-week studies with stable dosing schedules and dedicated refrigeration | | 20mg+ | 5–8mL | 2.5–4mg/mL | Multi-investigator shared use or concurrent protocols | High. 40+ punctures over 28 days | Only cost-effective if 90%+ consumed | Reserved for facilities with temperature-logged peptide refrigerators and concurrent ARA-290 studies |

What If: ARA-290 Vial Size Scenarios

What If My Protocol Gets Extended Mid-Study?

Order a second vial when you recognize the extension is likely. Don't try to stretch the first vial beyond 28 days post-reconstitution. Peptide degradation accelerates non-linearly after the stability window closes, and you cannot visually detect when potency has dropped below reliable thresholds. If you're on day 24 of a 28-day window and the protocol extends another two weeks, reconstitute a fresh vial immediately rather than risk compromising the final data points with degraded peptide.

What If I'm Running Multiple ARA-290 Studies Concurrently?

A single larger vial shared across studies is only appropriate if all studies are accessing the vial within the same 28-day window and your facility has temperature-logged refrigeration with access controls. If Study A needs 8mg over four weeks and Study B needs 6mg over three weeks with a one-week overlap, a 20mg vial accessed by both teams during the overlap period is cost-effective. If the studies are sequential or have minimal overlap, separate vials per study eliminate cross-contamination risk and provide clearer inventory tracking for publication documentation.

What If I'm Uncertain About My Protocol's Timeline?

Default to the smallest vial size that covers your minimum expected requirement plus 15% overage. A pilot study testing ARA-290 in a novel model with uncertain dosing schedules should start with a 2mg or 5mg vial even if preliminary calculations suggest 8mg total need. The risk of early termination or dose adjustment is high enough that paying a per-milligram premium is justified to avoid stranding capital in unused peptide. Scale up to larger vials only after the first cohort confirms the protocol is stable.

The Unforgiving Truth About ARA-290 Vial Sizing

Here's the honest answer: most labs waste 30–50% of their ARA-290 budget by choosing vial sizes that optimize unit cost instead of actual consumption. The peptide market incentivizes bulk purchasing with steep per-milligram discounts, but those discounts evaporate the moment you pour expired peptide down the chemical waste drain. A $400 purchase that delivers $150 of usable research and $250 of waste isn't a good deal. It's poor inventory management dressed up as cost savings.

The research community needs to stop treating peptides like bulk reagents. You wouldn't order a 5-liter bottle of an enzyme with a 30-day post-opening stability if your protocol only required 500mL. The same logic applies here. ARA-290's fixed degradation timeline after reconstitution makes it a perishable good, not a commodity. Facilities that treat it as perishable. Ordering closer to need, splitting large requirements across multiple smaller vials, and building procurement timelines around the 28-day window rather than fighting against it. Consistently report better data quality and lower per-study peptide costs than facilities chasing bulk discounts.

If you're storing reconstituted ARA-290 for more than 28 days or keeping lyophilised vials at room temperature because your freezer is full, you're compromising your data before the first injection. This isn't a guideline. It's biochemistry. Peptide bonds hydrolyze, methionine oxidizes, and receptor binding affinity drops in ways your assays may not detect until you're analyzing results and wondering why your treatment groups show unexplained variance. Choose ara-290 vial size based on what you'll actually use in 28 days, not what delivers the lowest price per milligram on the quote.

For facilities committed to reliable peptide research, Real Peptides offers small-batch ARA-290 synthesis with exact amino-acid sequencing and third-party purity verification. Every vial is manufactured to match your protocol's specific requirements rather than forcing you into standardized bulk sizes that don't align with actual consumption patterns.

The right vial size isn't the one with the best price per milligram. It's the one that gets fully consumed within the stability window while maintaining cold-chain integrity from reconstitution to final dose. If the math shows you need 7mg over three weeks, order an 8mg vial and discard 1mg. Not a 20mg vial where you'll discard 13mg. The smaller waste number is the correct procurement decision every time.

All compounds discussed on this page are sold for research use only and are not for human consumption.

References

Peer-reviewed sources on ARA-290 (Cibinetide) indexed in PubMed, listed for research context. Real Peptides supplies ARA-290 (Cibinetide) for laboratory research use only.

Mechanistic Approach for Protective Effect of ARA290, a Specific Ligand for the Erythropoietin/CD131 Heteroreceptor, against Cisplatin-Induced Nephrotoxicity, the Involvement of Apoptosis and Inflammation Pathways. Inflammation, 2023. PMID 36085231. doi:10.1007/s10753-022-01737-7
Early monocyte modulation by the non-erythropoietic peptide ARA 290 decelerates AD-like pathology progression. Brain, behavior, and immunity, 2022. PMID 34343617. doi:10.1016/j.bbi.2021.07.016
Synthesis and evaluation of (99m)Tc-DOTA-ARA-290 as potential SPECT tracer for targeting cardiac ischemic region. Iranian journal of basic medical sciences, 2021. PMID 35317117. doi:10.22038/IJBMS.2021.57565.12799
The Non-Erythropoietic EPO Analogue Cibinetide Inhibits Osteoclastogenesis In Vitro and Increases Bone Mineral Density in Mice. International journal of molecular sciences, 2021. PMID 35008482. doi:10.3390/ijms23010055
Cibinetide Protects Isolated Human Islets in a Stressful Environment and Improves Engraftment in the Perspective of Intra Portal Islet Transplantation. Cell transplantation, 2021. PMID 34498509. doi:10.1177/09636897211039739
An engineered non-erythropoietic erythropoietin-derived peptide, ARA290, attenuates doxorubicin induced genotoxicity and oxidative stress. Toxicology in vitro : an international journal published in association with BIBRA, 2020. PMID 32335150. doi:10.1016/j.tiv.2020.104864
Improvement of Islet Allograft Function Using Cibinetide, an Innate Repair Receptor Ligand. Transplantation, 2020. PMID 32345869. doi:10.1097/TP.0000000000003284
A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema. Journal of clinical medicine, 2020. PMID 32674280. doi:10.3390/jcm9072225

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Reconstituted ARA-290 maintains reliable potency for 28 days when stored continuously at 2–8°C in a temperature-controlled refrigerator. Beyond 28 days, peptide bond hydrolysis and methionine oxidation accelerate, reducing receptor binding affinity in ways that standard visual inspection cannot detect. Lyophilised ARA-290 before reconstitution remains stable for 24–36 months at −20°C, but once bacteriostatic water is added, the 28-day countdown is absolute.

No — freezing reconstituted peptide solutions causes ice crystal formation that disrupts the tertiary protein structure, permanently reducing biological activity. The damage is irreversible and occurs even with controlled slow-freeze protocols. If your protocol timeline exceeds 28 days, reconstitute a second vial rather than attempting to extend the first vial's life through freezing. Only lyophilised (freeze-dried) peptide before reconstitution can be stored at −20°C.

You will discard unused peptide when the 28-day post-reconstitution stability window expires, effectively paying full price for peptide you cannot use. A 20mg vial costs less per milligram than a 5mg vial, but if your protocol only requires 8mg, you're wasting 12mg of active compound. The effective cost per usable milligram becomes identical to or higher than smaller vials, with the added burden of disposing larger volumes of biological waste.

Multiply your per-dose requirement by total number of doses over 28 days, then add 10–15% overage for pipetting error and dead volume. If your protocol uses 2mg per injection twice weekly for four weeks, that is 16mg total — specify an 18mg vial to cover measurement variance. If your timeline exceeds 28 days, split the requirement into multiple smaller vials and reconstitute each one sequentially rather than accessing a single large vial beyond the stability window.

Multiple smaller vials cost 15–20% more per milligram upfront but eliminate waste from unused peptide, reduce contamination risk from repeated needle punctures, and provide insurance against total loss from a single storage failure. For protocols requiring more than 20mg total, the multi-vial strategy consistently delivers better data reliability and lower effective cost per usable milligram than single large vials, despite the higher unit pricing.

Yes — higher concentrations (above 5mg/mL) require dilution for sub-milligram dosing, and every dilution step introduces measurement error. A 10mg vial reconstituted with 2mL yields 5mg/mL, which is difficult to measure accurately for 500mcg doses using standard pipettes. Smaller vials reconstituted to 2–2.5mg/mL provide better precision for typical research dosing ranges without requiring secondary dilution.

No — lyophilised ARA-290 must be stored at −20°C before reconstitution to maintain long-term stability. Room temperature storage accelerates moisture absorption and peptide degradation even in sealed vials. Once you receive lyophilised vials, transfer them immediately to a −20°C freezer and store them there until you are ready to reconstitute. Vials left at room temperature for more than 48 hours may show reduced potency that you cannot detect visually.

Reconstitute a 5mg vial with 2mL bacteriostatic water to yield a 2.5mg/mL solution, which is compatible with standard research dosing protocols and pipetting equipment. This concentration allows accurate measurement of doses ranging from 250mcg to 2mg without requiring secondary dilution. Using less than 1.5mL makes the solution difficult to draw completely from the vial; using more than 3mL dilutes the peptide unnecessarily and increases the risk of measurement error.

Every needle puncture introduces contamination risk and allows air into the solution, accelerating oxidative degradation. For vials accessed daily over 28 days, this means 28 puncture events — which is acceptable if proper aseptic technique is maintained and the vial is stored in a dedicated peptide refrigerator. Vials requiring more than 40 punctures over their lifespan should be split into smaller volumes to reduce cumulative contamination exposure.

Discard the vial — temperature excursions above 8°C cause irreversible protein denaturation that neither visual inspection nor pH testing can detect. Even a single overnight exposure (8–12 hours at 20–25°C) degrades the methionine residues critical to receptor binding affinity. Using temperature-compromised peptide introduces uncontrolled variability into your data that you cannot correct retrospectively. Document the incident, order a replacement vial, and reconstitute fresh peptide.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA